News Sentiment

SLN sentiment intelligence

Silence Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.09 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-12.5% over one week, +35.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -12.5% Price reacting lower
Trend fit Trend active 35.9% over four weeks
Fair value -14.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 9
Investing.com 5
Stock Titan 4
simplywall.st 4
Investing.com South Africa 2
Insider Monkey 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 14
Analyst action 5
Regulatory and legal 4
Deals and strategy 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Pluang Direct company coverage

Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026

Willow Tree Research initiated coverage of Silence Therapeutics with a speculative Buy rating, citing the potential of its mRNAi drug divesiran (SLN124) for polycythemia vera. The drug's platform offers infrequent dosing and strong target knockdown, with promising early Phase 1 d

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 10:40
Source
Pluang
Investing.com South Africa Direct company coverage

Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com

The article reports on a Form 13D/A filing by Silence Therapeutics Plc for July 8th. This filing is a regulatory document typically used to disclose beneficial ownership of a company's shares. The article itself contains minimal content beyond the title and a stock symbol, indica

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 08:41
Source
Investing.com South Africa
Stock Titan Direct company coverage

Richard Griffiths updates Silence Therapeutics (SLN) holdings in latest 13D/A

Richard Griffiths has filed an Amendment No. 10 to his Schedule 13D, reporting a 21.7% beneficial ownership in Silence Therapeutics plc, totaling 30,844,458 ordinary shares. This update reflects open-market sales of 1,544,374 American Depositary Shares (ADSs) between June 29 and

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Griffiths trims Silence Therapeutics (SLN) stake with 1.54M ADS sales

Richard Ian Griffiths, a 10% owner of Silence Therapeutics (SLN), reported the sale of 1,544,374 American Depositary Shares (ADSs) across six open-market transactions between June 29 and July 6, 2026. These sales were conducted indirectly through entities like Cream Capital Limit

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 12:40
Source
Stock Titan
Insider Monkey Direct company coverage

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential

Cantor Fitzgerald initiated coverage of Silence Therapeutics plc (NASDAQ:SLN) with an Overweight rating, highlighting its siRNA pipeline and the potential of divesiran for polycythemia vera. The firm sees over 160% upside based on its valuation, ahead of Phase 2 results for dives

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 07:10
Source
Insider Monkey
TradingView Direct company coverage

Price to earnings forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN

The article focuses on the "Price to earnings forward" financial metric for Silence Therapeutics Plc (NASDAQ: SLN). It identifies the company as an American Depository Share listed on the Nasdaq Stock Market. The content is presented within the TradingView platform, noting that t

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN

This article provides the enterprise value to EBIT forward for Silence Therapeutics Plc (NASDAQ:SLN). It appears to be a financial data point from TradingView's platform, offering financial insights for the company. The content itself seems to be a placeholder for specific numeri

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN

The article displays the "Price to sales forward" metric for Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN) on TradingView. It indicates that the market was closed with no trades. The article is a financial data page rather than a detailed news report, providi

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 16:09
Source
TradingView
TradingView Direct company coverage

Silence Therapeutics plc Actuals & Estimates (OTC:SLNCF)

The article provides an overview of Silence Therapeutics, Plc. (SLNCF) stock, detailing its current price, historical highs and lows, market capitalization, volatility, and financial performance. It highlights the stock's recent price increases and answers frequently asked questi

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN

This article provides a financial snapshot of Silence Therapeutics Plc - American Depository Share (NASDAQ: SLN), focusing on its enterprise value to revenue forward metric. It details the company's financial data available on TradingView, along with general market information.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:40
Source
TradingView
TradingView Direct company coverage

Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN)

This page on TradingView provides financial actuals and estimates for Silence Therapeutics Plc (NASDAQ:SLN), an American Depository Share. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 08:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Silence Therapeutics Plc - American Depository Share – NASDAQ:SLN

This article presents the "Price to book forward" financial metric for Silence Therapeutics Plc (NASDAQ: SLN), an American Depository Share. The content is primarily a data point from TradingView's financial section, offering a specific valuation metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:39
Source
TradingView
Investing.com Nigeria Direct company coverage

Why is Silence Therapeutics stock surging today? By Investing.com

Silence Therapeutics (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, deeming the shares undervalued. The optimism stems from the potential of its lead asset, divesiran, particularly its Phase 2 SANRECO trial in

Tone
Positive 75/100
Event
Analyst action
Published
25 Jun 2026 16:41
Source
Investing.com Nigeria
Investing.com Direct company coverage

Why is Silence Therapeutics stock surging today?

Silence Therapeutics PLC (SLN) stock surged over 16% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating, citing the undervaluation of its lead asset, divesiran. The optimism is driven by the upcoming Phase 2 SANRECO trial results for polycythe

Tone
Positive 87/100
Event
Earnings
Published
25 Jun 2026 15:40
Source
Investing.com
Market source Direct company coverage

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

Silence Therapeutics (SLN) shares surged 26.0% to $9.16, driven by investor confidence in its long-term growth prospects, particularly for its lead candidate, divesiran, an siRNA therapy for polycythemia vera. The company anticipates topline results from its SANRECO phase II stud

Tone
Positive 63/100
Event
Earnings
Published
25 Jun 2026 07:48
Source
Market source
Investing.com Direct company coverage

Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade

Silence Therapeutics PLC (NASDAQ:SLN) shares surged 18.6% after Cantor Fitzgerald initiated coverage with an Overweight rating. Analyst Prakhar Agrawal highlighted the company's clinical-stage siRNA drug pipeline, particularly focusing on divesiran, a TMPRSS6 siRNA treatment for

Tone
Positive 72/100
Event
Analyst action
Published
24 Jun 2026 15:59
Source
Investing.com
Market source Direct company coverage

Coiled Therapeutics appoints biotech veteran Craig Tooman to board

Coiled Therapeutics, an AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director. Tooman brings over 30 years of pharmaceutical and biotechnology leadership experience and has been instrumental in raising significant capital

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 06:40
Source
Market source
Investing.com South Africa Direct company coverage

Form 8K Silence Therapeutics plc For: 23 June By Investing.com

This article is a Form 8K filing for Silence Therapeutics plc, dated June 23, 2026. It includes a disclaimer from Investing.com regarding the risks associated with trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 01:40
Source
Investing.com South Africa
TradingView Direct company coverage

Silence Therapeutics updates corporate presentation highlighting Divesiran Phase 2 topline timing and pipeline progress

Silence Therapeutics has issued an updated corporate presentation detailing key advancements in its pipeline. The company expects topline results for its Divesiran Phase 2 SANRECO trial in Q3 2026 and highlighted progress in multiple siRNA programs, including SLN312 and other pre

Tone
Positive 77/100
Event
Earnings
Published
24 Jun 2026 00:39
Source
TradingView
TradingKey Direct company coverage

Silence Therapeutics PLC (SLN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Silence Therapeutics PLC (SLN) has an earnings forecast score of 8.00, ranking 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a high of $75.00 and a low of $4.00. Based on ratings from 6 analysts, most recommend a

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 23:11
Source
TradingKey
Investing.com Direct company coverage

Silence Therapeutics shareholders approve all resolutions at annual meeting

Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. These resolutions included the re-appointment of directors, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as au

Tone
Positive 61/100
Event
Regulatory and legal
Published
18 Jun 2026 00:39
Source
Investing.com
Insider Monkey Direct company coverage

How Silence Therapeutics (SLN) Is Building the Divesiran Case Around Fewer Blood Draws in Polycythemia Vera

Silence Therapeutics (SLN) is developing divesiran, an experimental RNA-based treatment for polycythemia vera, a rare blood cancer. The company presented Phase 1 SANRECO study data showing that divesiran significantly reduced the need for frequent blood draws in patients. Silence

Tone
Positive 81/100
Event
Market update
Published
17 Jun 2026 11:16
Source
Insider Monkey
Investing.com Nigeria Direct company coverage

Silence Therapeutics shareholders approve all resolutions at annual meeting By Investing.com

Silence Therapeutics plc announced that all nine resolutions proposed at its 2026 Annual General Meeting of Shareholders were approved. Key approvals included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, the advisory approval of executive officer compen

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jun 2026 01:08
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Silence Therapeutics (SLN) investors approve directors, pay and auditors at 2026 AGM

Silence Therapeutics plc shareholders approved all nine resolutions at its 2026 Annual General Meeting. This included the re-appointment of directors Rhonda Hellums and James Ede-Golightly, advisory approval of executive compensation, and the re-appointment of PricewaterhouseCoop

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jun 2026 20:39
Source
Stock Titan
Sahm Direct company coverage

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Silence Therapeutics shares increased after the company released positive follow-up data from its Phase 1 SANRECO study for divesiran, a drug targeting polycythemia vera. The data showed potential improvements in symptoms and quality of life, along with reduced phlebotomy use. Wi

Tone
Positive 75/100
Event
Market update
Published
15 Jun 2026 01:40
Source
Sahm